News >

Pembrolizumab Improves PFS in Relapsed/Refractory Hodgkin Lymphoma

Gina Columbus @ginacolumbusonc
Published: Monday, Mar 02, 2020

Jonathan Cheng, MD

Jonathan Cheng, MD

Pembrolizumab (Keytruda) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared with brentuximab vedotin (Adcetris) in adult patients with relapsed/refractory classical Hodgkin lymphoma, meeting 1 of the dual primary endpoints of the phase III KEYNOTE-204 trial (NCT02684292).1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication